warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Brief Description  
The purpose of this trial is to determine the safety and tolerability of the novel combination of addition of ALT-801 to the standard of care of Cisplatin and Gemcitabine in patients with muscle invasive or metastatic urothelial cancer of the bladder, renal pelvis, ureters and urethra. Another objective is to estimate the anti-tumor activity of this combination of ALT-801, Cisplatin, and Gemcitabine by radiologic or pathologic anti-tumor response; progression free survival (assessed through end
Who may be Eligible  
Histologically or cytologically confirmed muscle invasive or metastatic urothelial cancer of the bladder, ureters, renal pelvis, and urethra, with a clinical plan that would potentially include cisplatin plus gemcitabine systemic therapy as standard of care. Patients >18 Patients who are HLA-A2 positive by serological typing or genotyping. No concurrent radiotherapy, other chemotherapy, other immunotherapy Normal Pulmonary Function Test evidenced by a FEV1 >/= to 70%
Speciality/Disorder  
Genitourinary Cancer
IRB Number  
05-11-04A
Principal Investigator  
Mahoney, John

For More Information, Contact  Tesa  M, Adams
Phone:  (704) 446-5145  Fax:  (704) 355-1352  
Email:  tesa.adams@carolinashealthcare.org
Address:1100 South Tryon Suite 220 Charlotte, NC 28203
Close